HEROZ has revised its consolidated forecast for the year ended April 2026, but the interesting bit is not a late surge in sales. Revenue is now seen at ¥6.424 billion versus ¥6.4 billion previously, company-defined EBITDA at ¥1.025 billion versus ¥1.0 billion, and operating profit at ¥523 million versus ¥500 million. Ordinary profit, however, is now expected at ¥408 million, down from ¥420 million. Net profit attributable to owners of parent is where the real swing sits, jumping to ¥376 million from ¥50 million, with forecast earnings per share rising to ¥24.75 from ¥3.29.
The revised guide replaces the forecast HEROZ published on December 12, 2025, and it would also mark a sharp improvement on the prior year's actuals, when the company reported ¥5.929 billion of revenue, ¥793 million of EBITDA, ¥306 million of operating profit, ¥228 million of ordinary profit and a ¥177 million net loss attributable to owners of parent. The bridge is mostly one-offs rather than a late operational breakout.
| Item | Expected amount | What HEROZ says |
|---|---|---|
| Gain on sale of subsidiary shares | 311,135 | Linked to the transfer of all shares in a consolidated subsidiary to GMO GlobalSign Holdings |
| Tax adjustment gain | 99,249 | Reflects deferred tax asset recognition tied to three capital transactions |
| Transaction-related costs | 114,838 | Costs associated with the capital transactions |
| Bitcoin valuation loss | 30,065 | Non-operating expense because period-end market value fell below acquisition cost |
The biggest positive is a ¥311.135 million gain on the sale of subsidiary shares, tied to an April 20 board decision to transfer all shares in a consolidated subsidiary to GMO GlobalSign Holdings. HEROZ also expects a ¥99.249 million tax adjustment gain after recognizing deferred tax assets linked to that disposal, a share exchange approved on April 14 that will make another consolidated subsidiary wholly owned, and the acquisition of 70% of AKM Consulting, effective May 1 and approved on April 20.
Offsetting items are less cheerful. HEROZ expects ¥114.838 million of transaction-related costs, and it will book a ¥30.065 million valuation loss on bitcoin held by the company because the period-end market value fell below acquisition cost. That loss is set to land in non-operating expenses, which helps explain why ordinary profit is the only major profit line to edge lower in the revised guide.
HEROZ says it revised the forecast after discussing the accounting impact of those capital transactions with its auditor and getting a clearer view of the amounts. Readers should therefore treat this as a disclosure about deal accounting settling into place, not a sudden reinvention of the underlying business. The company also says the forecast is based on currently available information and actual results may differ.